KR20140114892A - 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자 - Google Patents

고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자 Download PDF

Info

Publication number
KR20140114892A
KR20140114892A KR1020147023407A KR20147023407A KR20140114892A KR 20140114892 A KR20140114892 A KR 20140114892A KR 1020147023407 A KR1020147023407 A KR 1020147023407A KR 20147023407 A KR20147023407 A KR 20147023407A KR 20140114892 A KR20140114892 A KR 20140114892A
Authority
KR
South Korea
Prior art keywords
drug
drug delivery
polylactide
coating
thickness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147023407A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 마쉬
홍웬 마 리버스
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20140114892A publication Critical patent/KR20140114892A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147023407A 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자 Ceased KR20140114892A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
US61/589,681 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016713A Division KR102183727B1 (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자

Publications (1)

Publication Number Publication Date
KR20140114892A true KR20140114892A (ko) 2014-09-29

Family

ID=47630595

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020147023407A Ceased KR20140114892A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020207016713A Expired - Fee Related KR102183727B1 (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020207033455A Ceased KR20200133286A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020227010024A Ceased KR20220044379A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020237021933A Ceased KR20230104761A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형생분해성 또는 생체흡수성 미소구체 또는 미립자

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020207016713A Expired - Fee Related KR102183727B1 (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020207033455A Ceased KR20200133286A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020227010024A Ceased KR20220044379A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
KR1020237021933A Ceased KR20230104761A (ko) 2012-01-23 2013-01-22 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형생분해성 또는 생체흡수성 미소구체 또는 미립자

Country Status (17)

Country Link
US (5) US20130189369A1 (enExample)
EP (1) EP2806853B1 (enExample)
JP (1) JP6282231B2 (enExample)
KR (5) KR20140114892A (enExample)
CN (1) CN104136006B (enExample)
AU (3) AU2013212583A1 (enExample)
BR (1) BR112014017969A8 (enExample)
CA (1) CA2861348C (enExample)
DK (1) DK2806853T3 (enExample)
ES (1) ES2821526T3 (enExample)
HU (1) HUE050904T2 (enExample)
IL (2) IL233620A0 (enExample)
MX (1) MX364864B (enExample)
NZ (1) NZ627368A (enExample)
RU (1) RU2672596C2 (enExample)
WO (1) WO2013112434A1 (enExample)
ZA (1) ZA201405091B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
CN109310680B (zh) * 2016-06-30 2022-11-01 度瑞公司 长效配制物
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
BR112020000506A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4308106A4 (en) * 2021-03-15 2025-02-26 Oakwood Laboratories, Llc MICROSPHERE FORMULATIONS CONTAINING NALTREXONE AND METHODS OF PREPARING AND USING THE SAME
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN116869914A (zh) * 2023-05-30 2023-10-13 庄秉谚 无针注射系统的投递物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP1125577B1 (en) * 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
KR101892745B1 (ko) * 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子

Also Published As

Publication number Publication date
AU2017258895A1 (en) 2017-11-30
CA2861348A1 (en) 2013-08-01
CN104136006A (zh) 2014-11-05
KR20200133286A (ko) 2020-11-26
KR20200073292A (ko) 2020-06-23
US20240423922A1 (en) 2024-12-26
HK1204765A1 (en) 2015-12-04
BR112014017969A8 (pt) 2017-07-11
EP2806853A1 (en) 2014-12-03
NZ627368A (en) 2016-11-25
IL265620B (en) 2022-03-01
ZA201405091B (en) 2015-12-23
CN104136006B (zh) 2017-11-24
MX2014008857A (es) 2015-07-17
AU2019204957A1 (en) 2019-07-25
US20230390212A1 (en) 2023-12-07
US20240226022A1 (en) 2024-07-11
MX364864B (es) 2019-05-09
IL233620A0 (en) 2014-08-31
AU2013212583A1 (en) 2014-08-14
JP6282231B2 (ja) 2018-02-21
RU2014134420A (ru) 2016-03-20
AU2017258895B2 (en) 2019-04-18
KR102183727B1 (ko) 2020-11-27
IL265620A (en) 2019-05-30
HUE050904T2 (hu) 2021-01-28
CA2861348C (en) 2017-07-04
US20130189369A1 (en) 2013-07-25
WO2013112434A1 (en) 2013-08-01
KR20230104761A (ko) 2023-07-10
KR20220044379A (ko) 2022-04-07
US20200297650A1 (en) 2020-09-24
EP2806853B1 (en) 2020-07-08
JP2015504098A (ja) 2015-02-05
DK2806853T3 (da) 2020-09-28
BR112014017969A2 (enExample) 2017-06-20
RU2672596C2 (ru) 2018-11-16
ES2821526T3 (es) 2021-04-26

Similar Documents

Publication Publication Date Title
KR102183727B1 (ko) 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
JP7217247B2 (ja) ポリマータンパク質微粒子
EP2229150B1 (en) Systems and methods for delivery of materials
RU2521338C9 (ru) Способ лечения атрофической возрастной макулярной дегенерации
EP3373973B1 (en) Ocular compositions
JP6720447B2 (ja) 酸感受性薬剤の送達のための薬剤送達系
US20090148527A1 (en) Intraocular formulation
Patel et al. Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries
WO2017015616A1 (en) Ocular protein delivery
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
US20220054407A1 (en) Ocular compositions
Patel et al. Poly lactic glycolic acid (PLGA) as biodegradable polymer
HK1204765B (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
Arribada et al. The use of polymer blends in the treatment of ocular diseases. Pharmaceutics 2022, 14, 1431
Kim et al. Implantable delivery systems
Lundstrom Nanocarriers for the delivery of peptides and proteins
Khang Drug Delivery System Using Polymers (Lactide–Co-Glycolide)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140821

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190910

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200330

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190910

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200330

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20191107

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200520

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200427

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20200330

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191107

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190910

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200610